The DHCP letter initiated by Roche is intended to inform healthcare professionals about deregistration of approved indications for Gavreto® (pralsetinib) and removal from the South African pharmaceutical market....
This DHCP letter is initiated by Norvatis and is intended to inform healthcare professionals about important new user handling instructions for the Sybrava® (inclisiran) single-dose pre-filled syringe injection, to reduce the risks associated with administration of the product....
Healthcare professionals are drawn to the attention about the risk of error in the administration of IV tranexamic acid. Tranexamic acid is for IV use only. However, there is a potential for confusion of tranexamic acid with other injectables which could result in inadvertent intrathecal...
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the companies listed below would like to inform you about recommended calculations of contraception duration after completion of therapy with genotoxic anticancer medicines (including potential metabolites)....
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Abbott Laboratories SA (Pty) Ltd, would like to inform you that Phenylephrine hydrochloric injectionTM has been up scheduled from Schedule 1 to Schedule 4 status. However, Abbott is experiencing unforeseen delays in the implementation...
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the companies listed in the attached document would like to inform you about recommended calculations of contraception duration after completion of therapy with genotoxic anticancer medicines (Including potential genotoxic metabolites)....
Dear Healthcare Professional, Aspen Pharmacare, Adcock Ingram Limited, Pharma Dynamics and Sandoz SA (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA), would like to draw your attention to the following important safety information associated with the use of valaciclovir/aciclovir-containing medicines registered...
Dear Healthcare Professional, In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you about the risk of drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of valaciclovir/aciclovir- containing medicines....
Dear Healthcare Professional In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Roche Products (Pty) Ltd would like to inform you of the potential missing PI and PIL in folding boxes of Perjeta® (pertuzumab) 420mg/14mL infusion....
Dear Healthcare Professional In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Roche Products (Pty) Ltd would like to inform you of the potential missing PI and PIL in folding boxes of Hemlibra® (emicizumab) 60 mg/0,4 mL solution for injection. The purpose of this...
